靶向m6A甲基化用于肝细胞癌的早期诊断和精准医疗。

IF 6 2区 医学 Q1 ONCOLOGY
Qing-Kang Zheng, Ya-Nan Shi, Ming-Yuan Yang, Yi-Yuan Xie, Kai Sun, Huan-Zhang Niu
{"title":"靶向m6A甲基化用于肝细胞癌的早期诊断和精准医疗。","authors":"Qing-Kang Zheng, Ya-Nan Shi, Ming-Yuan Yang, Yi-Yuan Xie, Kai Sun, Huan-Zhang Niu","doi":"10.1186/s12935-025-03923-7","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) ranks as a significant global malignancy, occupying the sixth position in incidence and the third in cancer-related mortality. Despite this, the mechanisms underlying HCC progression remain insufficiently understood. m6A modification is one of the most common post-transcriptional modifications in eukaryotic mRNA, regulated by methyltransferases, demethylases, and m<sup>6</sup>A-binding proteins. Proteins specialized in m6A recognition selectively bind to m6A-modified RNA, influencing processes such as splicing, maturation, nucleation, degradation, and translation. Current research, both domestic and international, primarily explores how m6A modification and its associated proteins affect malignant cell proliferation, migration, invasion, metastasis, and drug resistance. However, the role of m6A-related proteins in tumor progression in HCC remains poorly characterized. This review elucidates the composition, mechanisms, and biological functions of m6A methylation modification proteins in HCC progression, alongside recent advancements in m6A-related biomarker discovery and immunotherapeutic developments, aiming to enhance early clinical diagnosis and facilitate targeted drug development for HCC.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"286"},"PeriodicalIF":6.0000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302885/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.\",\"authors\":\"Qing-Kang Zheng, Ya-Nan Shi, Ming-Yuan Yang, Yi-Yuan Xie, Kai Sun, Huan-Zhang Niu\",\"doi\":\"10.1186/s12935-025-03923-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hepatocellular carcinoma (HCC) ranks as a significant global malignancy, occupying the sixth position in incidence and the third in cancer-related mortality. Despite this, the mechanisms underlying HCC progression remain insufficiently understood. m6A modification is one of the most common post-transcriptional modifications in eukaryotic mRNA, regulated by methyltransferases, demethylases, and m<sup>6</sup>A-binding proteins. Proteins specialized in m6A recognition selectively bind to m6A-modified RNA, influencing processes such as splicing, maturation, nucleation, degradation, and translation. Current research, both domestic and international, primarily explores how m6A modification and its associated proteins affect malignant cell proliferation, migration, invasion, metastasis, and drug resistance. However, the role of m6A-related proteins in tumor progression in HCC remains poorly characterized. This review elucidates the composition, mechanisms, and biological functions of m6A methylation modification proteins in HCC progression, alongside recent advancements in m6A-related biomarker discovery and immunotherapeutic developments, aiming to enhance early clinical diagnosis and facilitate targeted drug development for HCC.</p>\",\"PeriodicalId\":9385,\"journal\":{\"name\":\"Cancer Cell International\",\"volume\":\"25 1\",\"pages\":\"286\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302885/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12935-025-03923-7\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03923-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

肝细胞癌(HCC)是全球重要的恶性肿瘤,发病率居第六位,癌症相关死亡率居第三位。尽管如此,HCC进展的机制仍未得到充分了解。m6A修饰是真核生物mRNA中最常见的转录后修饰之一,受甲基转移酶、去甲基化酶和m6A结合蛋白的调控。专门识别m6A的蛋白质选择性地结合m6A修饰的RNA,影响剪接、成熟、成核、降解和翻译等过程。目前国内外的研究主要是探讨m6A修饰及其相关蛋白对恶性细胞增殖、迁移、侵袭、转移及耐药的影响。然而,m6a相关蛋白在HCC中肿瘤进展中的作用仍然知之甚少。本文综述了m6A甲基化修饰蛋白在HCC进展中的组成、机制和生物学功能,以及m6A相关生物标志物的发现和免疫治疗的最新进展,旨在加强HCC的早期临床诊断和促进靶向药物的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.

Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.

Targeting m6A methylation for early diagnosis and precision medicine in hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) ranks as a significant global malignancy, occupying the sixth position in incidence and the third in cancer-related mortality. Despite this, the mechanisms underlying HCC progression remain insufficiently understood. m6A modification is one of the most common post-transcriptional modifications in eukaryotic mRNA, regulated by methyltransferases, demethylases, and m6A-binding proteins. Proteins specialized in m6A recognition selectively bind to m6A-modified RNA, influencing processes such as splicing, maturation, nucleation, degradation, and translation. Current research, both domestic and international, primarily explores how m6A modification and its associated proteins affect malignant cell proliferation, migration, invasion, metastasis, and drug resistance. However, the role of m6A-related proteins in tumor progression in HCC remains poorly characterized. This review elucidates the composition, mechanisms, and biological functions of m6A methylation modification proteins in HCC progression, alongside recent advancements in m6A-related biomarker discovery and immunotherapeutic developments, aiming to enhance early clinical diagnosis and facilitate targeted drug development for HCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.90
自引率
1.70%
发文量
360
审稿时长
1 months
期刊介绍: Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信